Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab placebo-controlled synovial analysis study in rheumatoid arthritis
2008-003011-12Phase 2Completed
- Sponsor
- University of Leeds
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Tocilizumab + methotrexate/background DMARD with Placebo + methotrexate/background DMARD (2 arms). Primary endpoints: Change in synovial volume on knee MRI at 4 weeks, Change in bone oedema on knee MRI at 4 weeks and 1 more. Started Apr 2009; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2008-003011-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003011-12.